Bioavailable dietary phosphate, a mediator of cardiovascular disease, may be decreased with plant-based diets, phosphate binders, niacin, and avoidance of phosphate additives

Nutrition

Volumn 30, Issue 7-8, 2014, Pages 739-747

  McCarty, Mark F ^a   DiNicolantonio, James J ^b  

^a Catalytic Longevity   (United States)

^b Wegmans Pharmacy   (United States)

Author keywords

Cardiovascular risk; Fibroblast growth factor 23; Magnesium; Niacin; Parathyroid hormone; Phosphate; Vitamin D; Vitamin K

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FOOD ADDITIVE; MAGNESIUM; NAPI 2 B PROTEIN; NICOTINIC ACID; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHATE TRANSPORTER; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN K GROUP; CALCIUM; FIBROBLAST GROWTH FACTOR; PHOSPHATE; PHOSPHATE INTAKE; TRACE ELEMENT;

BLOOD VESSEL CALCIFICATION; CARBOXYLATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CYTOKINE PRODUCTION; DIET RESTRICTION; FOOD COMPOSITION; GASTROINTESTINAL ABSORPTION; HIGH RISK PATIENT; HUMAN; INSULIN SENSITIVITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; THERAPY EFFECT; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION; BLOOD; CARDIOVASCULAR DISEASES; CHEMISTRY; DIET;

CALCIUM; CARDIOVASCULAR DISEASES; DIET; FIBROBLAST GROWTH FACTORS; FOOD ADDITIVES; HUMANS; MICRONUTRIENTS; NIACIN; PARATHYROID HORMONE; PHOSPHATES; PHOSPHORUS, DIETARY;

EID: 84903376102     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2013.12.010     Document Type: Review

References (196)

1. Tonelli M., Sacks F., Pfeffer M., Gao Z., Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005, 112:2627-2633.
2. Dhingra R., Sullivan L.M., Fox C.S., Wang T.J., D'Agostino R.B., Kannel W.B., et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007, 167:879-885.
3. Dhingra R., Gona P., Benjamin E.J., Wang T.J., Aragam J., D'Agostino R.B., et al. Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community. Eur J Heart Fail 2010, 12:812-818.
4. van Kuijk J.P., Flu W.J., Chonchol M., Valentijm T.M., Verhagen H.J., Bax J.J., et al. Elevated preoperative phosphorus levels are an independent risk factor for cardiovascular mortality. Am J Nephrol 2010, 32:163-168.
5. Larsson T.E., Olauson H., Hagstrom E., et al. Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community. Arterioscler Thromb Vasc Biol 2010, 30:333-339.
6. Chonchol M., Dale R., Schrier R.W., Estacio R. Serum phosphorus and cardiovascular mortality in type 2 diabetes. Am J Med 2009, 122:380-386.
7. Onufrak S.J., Bellasi A., Cardarelli F., Vaccarino V., Muntner P., Shaw L.J., et al. Investigation of gender heterogeneity in the associations of serum phosphorus with incident coronary artery disease and all-cause mortality. Am J Epidemiol 2009, 169:67-77.
8. Foley R.N., Collins A.J., Ishani A., Kalra P.A. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2008, 156:556-563.
9. Ellam T.J., Chico T.J. Phosphate: The new cholesterol? The role of the phosphate axis in non-uremic vascular disease. Atherosclerosis 2011, 220:310-318.
10. Kalaitzidis R., Tsimihodimos V., Bairaktari E., Siamopoulos K.C., Elisaf M. Disturbances of phosphate metabolism: another feature of metabolic syndrome. Am J Kidney Dis 2005, 45:851-858.
11. Lippi G., Montagnana M., Salvagno G.L., Targher G., Guidi G.C. Relationship between serum phosphate and cardiovascular risk factors in a large cohort of adult outpatients. Diabetes Res Clin Pract 2009, 84:e3-e5.
12. de Boer I.H., Rue T.C., Kestenbaum B. Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2009, 53:399-407.
13. Park W., Kim B.S., Lee J.E., Huh J.K., Kim B.J., Sung K.C., et al. Serum phosphate levels and the risk of cardiovascular disease and metabolic syndrome: a double-edged sword. Diabetes Res Clin Pract 2009, 83:119-125.
14. Ruan L., Chen W., Srinivasan S.R., Xu J., Toprak A., Berenson G.S. Relation of serum phosphorus levels to carotid intima-media thickness in asymptomatic young adults (from the Bogalusa Heart Study). Am J Cardiol 2010, 106:793-797.
15. Onufrak S.J., Bellasi A., Shaw L.J., Herzog C.A., Cardarelli F., Wilson P.W., et al. Phosphorus levels are associated with subclinical atherosclerosis in the general population. Atherosclerosis 2008, 199:424-431.
16. Kendrick J., Ix J.H., Targher G., Smits G., Chonchol M. Relation of serum phosphorus levels to ankle brachial pressure index (from the Third National Health and Nutrition Examination Survey). Am J Cardiol 2010, 106:564-568.
17. Ix J.H., de Boer I.H., Peralta C.A., Adney K.L., Duprez D.A., Jenny N.S., et al. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009, 4:609-615.
18. Zhang Y., Post W.S., Dalal D., Bansal S., Blasco-Colmenares E., Jan de Beur S., et al. Serum 25-hydroxyvitamin D, calcium, phosphorus, and electrocardiographic QT interval duration: findings from NHANES III and ARIC. J Clin Endocrinol Metab 2011, 96:1873-1882.
19. Rasouli M., Kiasari A.M. Serum calcium and phosphorus associate with the occurrence and severity of angiographically documented coronary heart disease, possibly through correlation with atherogenic (apo)lipoproteins. Clin Chem Lab Med 2006, 44:43-50.
20. Giachelli C.M. The emerging role of phosphate in vascular calcification. Kidney Int 2009, 75:890-897.
21. Mathew S., Tustison K.S., Sugatani T., Chaudhary L.R., Rifas L., Hruska K.A. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 2008, 19:1092-1105.
22. Ohnishi M., Razzaque M.S. Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J 2010, 24:3562-3571.
23. Kuro-o M. A potential link between phosphate and aging-lessons from Klotho-deficient mice. Mech Ageing Dev 2010, 131:270-275.
24. Ferro C.J., Chue C.D., Steeds R.P., Townend J.N. Is lowering phosphate exposure the key to preventing arterial stiffening with age?. Heart 2009, 95:1770-1772.
25. Morishita K., Shirai A., Kubota M., Katakura Y., Nabeshima Y., Takeshiga K., et al. The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr 2001, 131:3182-3188.
26. Merideth M.A., Gordon L.B., Clauss S., Sachdev V., Smith A.C., Perry M.B., et al. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 2008, 358:592-604.
27. Baum M., Schiavi S., Dwarakanath V., Quigley R. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int 2005, 68:1148-1153.
28. Gattineni J., Bates C., Twombley K., Dwarakanath V., Robinson M.L., Goetz R., et al. FGF23 decreases renal NaPi-2 a and NaPi-2 c expression and induces hypophosphatemia invivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 2009, 297:F282-F291.
29. Bergwitz C., Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010, 61:91-104.
30. Bacic D., Schulz N., Biber J., Kaissling B., Murer H., Wagner C.A. Involvement of the MAPK-kinase pathway in the PTH-mediated regulation of the proximal tubule type IIa Na+/Pi cotransporter in mouse kidney. Pflugers Arch 2003, 446:52-60.
31. Perwad F., Zhang M.Y., Tenenhouse H.S., Portale A.A. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism invivo and suppresses 25-hydroxyvitamin D-1 alpha-hydroxylase expression invitro. Am J Physiol Renal Physiol 2007, 293:F1577-F1583.
32. Jones G., Prosser D.E., Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24 A1): Its important role in the degradation of vitamin D. Arch Biochem Biophys 2012, 523:9-18.
33. Krajisnik T., Bjorklund P., Marsell R., Ljunggren O., Akerstrom G., Jonsson K.B., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1 alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007, 195:125-131.
34. Lee D.B., Walling M.W., Brautbar N. Intestinal phosphate absorption: Influence of vitamin D and non-vitamin D factors. Am J Physiol 1986, 250:G369-G373.
35. Miyamoto K., Ito M., Kuwahata M., Kato S., Segawa H. Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23. Ther Apher Dial 2005, 9:331-335.
36. Mirza M.A., Larsson A., Lind L., Larsson T.E. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009, 205:385-390.
37. Mirza M.A., Larsson A., Melhus H., Lind L., Larsson T.E. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009, 207:546-551.
38. Mirza M.A., Hansen T., Johansson L., Ahlstrom H., Larsson A., Lind L., et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 2009, 24:3125-3131.
39. Parker B.D., Schurgers L.J., Brandenburg V.M., Christenson R.H., Vermeer C., Ketteler M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study. Ann Intern Med 2010, 152:640-648.
40. Kanbay M., Nicoleta M., Selcoki Y., Ikizek M., Aydin M., Eryonucu B., et al. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol 2010, 5:1780-1786.
41. Arnlov J., Carlsson A.C., Sundstrom J., Ingelsson E., Larsson A., Lind L., et al. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol 2013, 8:781-786.
42. Arnlov J., Carlsson A.C., Sundstrom J., Ingelsson E., Larsson A., Lind L., et al. Higher fibroblast growth factor-23 increases the risk of all-cause andcardiovascular mortality in the community. Kidney Int 2013, 83:160-166.
43. Faul C., Amaral A.P., Oskouei B., Hu M.C., Sloan A., Isakova T., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121:4393-4408.
44. Wolf M., Molnar M.Z., Amaral A.P., Czira M.E., Rudas A., Ujszaszi A., et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011, 22:956-966.
45. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012, 82:737-747.
46. Heine G.H., Seiler S., Fliser D. FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrol Dial Transplant 2012, 27:3072-3081.
47. McCarty M.F. A moderately low phosphate intake may provide health benefits analogous to those conferred by UV light-a further advantage of vegan diets. Med Hypotheses 2003, 61:543-560.
48. Anderson J.L., Vanwoerkom R.C., Horne B.D., Bair T.L., May H.T., Lappe D.L., et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?. Am Heart J 2011, 162:331-339.
49. McCarty M.F. Nutritional modulation of parathyroid hormone secretion may influence risk for left ventricular hypertrophy. Med Hypotheses 2005, 64:1015-1021.
50. Chang E., Donkin S.S., Teegarden D. Parathyroid hormone suppresses insulin signaling in adipocytes. Mol Cell Endocrinol 2009, 307:77-82.
51. Huang C., Shapses S.A., Wang X. Association of plasma parathyroid hormone with metabolic syndrome and risk for cardiovascular disease. Endocr Pract 2013, 19:1-19.
52. Reis J.P., von M.D., Kritz-Silverstein D., Wingard D.L., Barrett-Connor E. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care 2007, 30:1549-1555.
53. Roislien J., Van C.B., Hjelmesaeth J. Parathyroid hormone is a plausible mediator for the metabolic syndrome in the morbidly obese: a cross-sectional study. Cardiovasc Diabetol 2011, 10:17.
54. Alemzadeh R., Kichler J. Parathyroid hormone is associated with biomarkers of insulin resistance and inflammation, independent of vitamin D status, in obese adolescents. Metab Syndr Relat Disord 2012, 10:422-429.
55. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110:229-238.
56. Verma S., Gupta M., Holmes D.T., Xu L., Teoh H., Gupta S., et al. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J 2011, 32:2135-2142.
57. Tomaschitz A., Pilz S., Ritz E., Morganti A., Grammer T., Amrein K., et al. Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. Eur Heart J 2011, 32:2642-2649.
58. Gonzalez M.C., Cohen H.W., Sealey J.E., Laragh J.H., Alderman M.H. Enduring direct association of baseline plasma Renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am J Hypertens 2011, 24:1181-1186.
59. Daimon M., Konta T., Oizumi T., Karasawa S., Kaino W., Takase K., et al. Higher plasma renin activity is a risk factor for total mortality in older Japanese individuals: the Takahata study. Metabolism 2012, 61:504-511.
60. Takeda M., Yamashita T., Sasaki N., Nakajima K., Kita T., Shinohara M., et al. Oral administration of an active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions. Arterioscler Thromb Vasc Biol 2010, 30:2495-2503.
61. Oh J., Weng S., Felton S.K., Bandare S., Riek A., Butler B., et al. 1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 2009, 120:687-698.
62. Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am 2010, 39:365-379.
63. Holt P.R., Arber N., Halmos B., Forde K., Kissileff H., McGlynn K.A., et al. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev 2002, 11:113-119.
64. Lou Y.R., Qiao S., Talonpoika R., Syvala H., Tuohimaa P. The role of vitamin D3 metabolism in prostate cancer. J Steroid Biochem Mol Biol 2004, 92:317-325.
65. Vieth R. How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology. Anticancer Res 2009, 29:3675-3684.
66. Li H., Stampfer M.J., Hollis J.B., Mucci L.A., Gaziano J.M., Hunter D., et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007, 4:e103.
67. Newmark H.L., Heaney R.P. Dairy products and prostate cancer risk. Nutr Cancer 2010, 62:297-299.
68. Lau W.L., Pai A., Moe S.M., Giachelli C.M. Direct effects of phosphate on vascular cell function. Adv Chronic Kidney Dis 2011, 18:105-112.
69. Shuto E., Taketani Y., Tanaka R., Harada N., Isshiki M., Sato M., et al. Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 2009, 20:1504-1512.
70. Di Marco G.S., Hausberg M., Hillebrand U., Rustemeyer P., Wittkowski W., Lang D., et al. Increased inorganic phosphate induces human endothelial cell apoptosis invitro. Am J Physiol Renal Physiol 2008, 294:F1381-F1387.
71. Mirza M.A., Alsio J., Hammarstedt A., Erben R.G., Michaelsson K., Tivesten A., et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 2011, 31:219-227.
72. Wojcik M., Dolezal-Oltarzewska K., Janus D., Drozdz D., Sztefko K., Starzyk J.B. FGF23 contributes to insulin sensitivity in obese adolescents-preliminary results. Clin Endocrinol (Oxf) 2012, 77:537-540.
73. Hjelmesaeth J., Hofso D., Aasheim E.T., Jenssen T., Moan J., Hager H., et al. Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: a cross-sectional study. Cardiovasc Diabetol 2009, 8:7.
74. Kjeldsen S.E., Os I., Westheim A., Frederichsen P., Hjermann I., Eide I.K., et al. Decreased serum phosphate in essential hypertension. Related to increased sympathetic tone. Am J Hypertens 1988, 1:403-409.
75. Lee Z.S., Critchley J.A., Tomlinson B., Young R.P., Thomas G.N., Cockram C.S., et al. Urinary epinephrine and norepinephrine interrelations with obesity, insulin, and the metabolic syndrome in Hong Kong Chinese. Metabolism 2001, 50:135-143.
76. Brunner E.J., Hemingway H., Walker B.R., Page M., Clarke P., Juneja M., et al. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 2002, 106:2659-2665.
77. Ellam T., Wilkie M., Chamberlain J., Crossman D., Eastell R., Francis S., et al. Dietary phosphate modulates atherogenesis and insulin resistance in apolipoprotein E knockout mice-brief report. Arterioscler Thromb Vasc Biol 2011, 31:1988-1990.
78. Alvarez J.A., Ashraf A.P., Hunter G.R., Gower B.A. Serum 25-hydroxyvitamin D and parathyroid hormone are independent determinants of whole-body insulin sensitivity in women and may contribute to lower insulin sensitivity in African Americans. Am J Clin Nutr 2010, 92:1344-1349.
79. Portale A.A., Halloran B.P., Morris R.C. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 1989, 83:1494-1499.
80. Osuka S., Razzaque M.S. Can features of phosphate toxicity appear in normophosphatemia?. J Bone Miner Metab 2012, 30:10-18.
81. Ferrari S.L., Bonjour J.P., Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005, 90:1519-1524.
82. Antoniucci D.M., Yamashita T., Portale A.A. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006, 91:3144-3149.
83. Burnett S.M., Gunawardene S.C., Bringhurst F.R., Juppner H., Lee H., Finkelstein J.S. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006, 21:1187-1196.
84. Vervloet M.G., van Ittersum F.J., Buttler R.M., Heijboer A.C., Blankenstein M.A., ter Wee P.M. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol 2011, 6:383-389.
85. Gutierrez O.M., Wolf M., Taylor E.N. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol 2011, 6:2871-2878.
86. Calvo M.S., Kumar R., Heath H. Persistently elevated parathyroid hormone secretion and action in young women after four weeks of ingesting highphosphorus, low calcium diets. J Clin Endocrinol Metab 1990, 70:1334-1340.
87. Kemi V.E., Rita H.J., Karkkainen M.U., Viljakainen H.T., Laaksonen M.M., Outila T.A., et al. Habitual high phosphorus intakes and foods with phosphate additives negatively affect serum parathyroid hormone concentration: a cross-sectional study on healthy premenopausal women. Public Health Nutr 2009, 12:1885-1892.
88. Kuhlmann M.K. Practical approaches to management of hyperphosphatemia: can we improve the current situation?. Blood Purif 2007, 25:120-124.
89. Kalantar-Zadeh K., Gutekunst L., Mehrotra R., Kovesdy C.P., Bross R., Shinaberger C.S., et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010, 5:519-530.
90. Moe S.M., Zidehsarai M.P., Chambers M.A., Jackman L.A., Radcliffe J.S., Trevino L.L., et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:257-264.
91. Scialla J.J., Appel L.J., Wolf M., Yang W., Zhang X., Sozio S.M., et al. Plant protein intake is associated with fibroblast growth factor 23 and serum bicarbonate levels in patients with chronic kidney disease: the Chronic Renal Insufficiency Cohort study. J Ren Nutr 2012, 22:379-388.
92. Uribarri J., Calvo M.S. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology?. Semin Dial 2003, 16:186-188.
93. Gutierrez O.M. Sodium- and phosphorus-based food additives: persistent but surmountable hurdles in the management of nutrition in chronic kidney disease. Adv Chronic Kidney Dis 2013, 20:150-156.
94. Calvo M.S., Uribarri J. Public health impact of dietary phosphorus excess on bone and cardiovascular health in the general population. Am J Clin Nutr 2013, 98:6-15.
95. de Francisco A.L., Leidig M., Covic A.C., Kettleler M., Benedyck-Lorens E., Mircescu G.M., et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010, 25:3707-3717.
96. McCarty M.F. Point of view-a role for "nutritional insurance" supplementation in preventive medicine. Med Hypotheses 1981, 7:171-185.
97. Shechter M., Sharir M., Labrador M.J., Forrester J., Silver B., Bairey Merz C.N. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000, 102:2353-2358.
98. Shechter M. The role of magnesium as antithrombotic therapy. Wien Med Wochenschr 2000, 150:343-347.
99. Pokan R., Hofmann P., von Duvillard S.P., Smekal G., Wonisch M., Lettner K., et al. Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients. Br J Sports Med 2006, 40:773-778.
100. Lopez-Ridaura R., Willett W.C., Rimm E.B., Liu S., Stampfer M.J., Manson J.E., et al. Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 2004, 27:134-140.
101. He K., Liu K., Daviglus M.L., Loria C.M., Van Horn L., Jacobs D.R., et al. Magnesium intake and incidence of metabolic syndrome among young adults. Circulation 2006, 113:1675-1682.
102. Song Y., Sesso H.D., Manson J.E., Cook N.R., Buring J.E., Liu S. Dietary magnesium intake and risk of incident hypertension among middle-aged and older US women in a 10-year follow-up study. Am J Cardiol 2006, 98:1616-1621.
103. Schulze M.B., Schulz M., Heidemann C., Schienkiewitz A., Hoffmann K., Boeing H. Fiber and magnesium intake and incidence of type 2 diabetes: aprospective study and meta-analysis. Arch Intern Med 2007, 167:956-965.
104. Wark P.A., Lau R., Norat T., Kampman E. Magnesium intake and colorectal tumor risk: a case-control study and meta-analysis. Am J Clin Nutr 2012, 96:622-631.
105. Chen G.C., Pang Z., Liu Q.F. Magnesium intake and risk of colorectal cancer: a meta-analysis of prospective studies. Eur J Clin Nutr 2012, 66:1182-1186.
106. Nordin B.E. The effect of calcium supplementation on bone loss in 32 controlled trials in postmenopausal women. Osteoporos Int 2009, 20:2135-2143.
107. Lips P., Bouillon R., van Schoor N.M., Vanderschueren D., Verscheuren S., Kuchak N., et al. Reducing fracture risk with calcium and vitamin D. Clin Endocrinol (Oxf) 2010, 73:277-285.
108. Shantouf R., Ahmadi N., Flores F., Tiano J., Gopal A., Kalanter-Zadeh K., et al. Impact of phosphate binder type on coronary artery calcification in hemodialysis patients. Clin Nephrol 2010, 74:12-18.
109. West S.L., Swan V.J., Jamal S.A. Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population. Clin J Am Soc Nephrol 2010, 5(Suppl 1):S41-S47.
110. Navaneethan S.D., Palmer S.C., Craig J.C., Elder G.J., Strippoli G.F. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009, 54:619-637.
111. Block G.A., Spiegel D.M., Ehrlich J., Mehta R., Lingbergh J., Dreisbach A., et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005, 68:1815-1824.
112. Di Iorio B., Molony D., Bell C., Cuccienello E., Bellizzi V., Russo D., et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 2013, 62:771-778.
113. St Peter W.L., Liu J., Weinhandl E., Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008, 51:445-454.
114. Nelson R. Novel phosphate binder is effective in patients on haemodialysis. Lancet 2002, 360:1483.
115. Jamal S.A., Fitchett D., Lok C.E., Mendelssohn D.C., Tsuyuki R.T. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant 2009, 24:3168-3174.
116. Bolland M.J., Avenell A., Baron J.A., Grey A., MacLennan G.S., Gamble G.D., et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010, 341:c3691.
117. Bolland M.J., Grey A., Avenell A., Gamble G.D., Reid I.R. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011, 342:d2040.
118. Nordin B.E., Lewis J.R., Daly R.M., Horowitz J., Metcalfe A., Lange K., et al. The calcium scare-what would Austin Bradford Hill have thought?. Osteoporos Int 2011, 22:3073-3077.
119. Samelson E.J., Booth S.L., Fox C.S., Tucker K.L., Wang T.J., Hoffmann Y., et al. Calcium intake is not associated with increased coronary artery calcification: the Framingham Study. Am J Clin Nutr 2012, 96:1274-1280.
120. Petrov V., Lijnen P. Modification of intracellular calcium and plasma renin by dietary calcium in men. Am J Hypertens 1999, 12:1217-1224.
121. McCarty M.F. Concurrent treatment with an ACE inhibitor may amplify the utility of calcium supplementation for control of hypertension. Med Hypotheses 2004, 63:818-822.
122. Tomaschitz A., Pilz S., Ritz E., Grammer T., Dreschler C., Boehm B.O., et al. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta 2010, 411:1354-1360.
123. Wang L., Manson J.E., Song Y., Sesso H.D. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010, 152:315-323.
124. Drechsler C., Pilz S., Obermayer-Pietsch B., Verduijn M., Tomaschitz A., Krane V., et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 2010, 31:2253-2261.
125. Daroux M., Shenouda M., Bacri J.L., Lemaitre V., Vanhille P., Bataille P. Vitamin D2 versus vitamin D3 supplementation in hemodialysis patients: a comparative pilot study. J Nephrol 2013, 26:152-157.
126. Kandula P., Dobre M., Schold J.D., Schreiber M.J., Mehrotra R., Navaneethan S.D. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011, 6:50-62.
127. Jean G., Terrat J.C., Vanel T., Hurot J.M., Lorriaux C., Mayor B., et al. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clin Pract 2008, 110:c58-c65.
128. Jean G., Souberbielle J.C., Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 2009, 24:3799-3805.
129. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J.M., Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003, 349:446-456.
130. Jean G., Lataillade D., Genet L., Legrand E., Kuentz F., Moreau-Gaudry X., et al. Impact of hypovitaminosis D and alfacalcidol therapy on survival of hemodialysis patients: results from the French ARNOS study. Nephron Clin Pract 2011, 118:c204-c210.
131. Ogawa M., Ogawa T., Inoue T., Otsuka K., Nitta K. Effect of alfacalcidol therapy on the survival of chronic hemodialysis patients. Ther Apher Dial 2012, 16:248-253.
132. Shoji T., Shinohara K., Kimoto E., Emoto M., Tahara H., Koyama H., et al. Lowerrisk for cardiovascular mortality in oral 1 alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004, 19:179-184.
133. Salem S., Bruck H., Bahlmann F.H., Peter M., Passlick-Deetjen J., Kretschmer A., et al. Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol 2012, 35:31-39.
134. Turgut F., Kanbay M., Metin M.R., Uz E., Akcay A., Covic A. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 2008, 40:1075-1082.
135. Shechter M. Magnesium and cardiovascular system. Magnes Res 2010, 23:60-72.
136. Bo S., Pisu E. Role of dietary magnesium in cardiovascular disease prevention, insulin sensitivity and diabetes. Curr Opin Lipidol 2008, 19:50-56.
137. Nielsen F.H., Milne D.B., Klevay L.M., Gallagher S., Johnson L. Dietary magnesium deficiency induces heart rhythm changes, impairs glucose tolerance, and decreases serum cholesterol in post menopausal women. J Am Coll Nutr 2007, 26:121-132.
138. Rodriguez-Moran M., Simental Mendia L.E., Zambrano G.G., Guerrero-Romero F. The role of magnesium in type 2 diabetes: a brief based-clinical review. Magnes Res 2011, 24:156-162.
139. Ryder K.M., Shorr R.I., Bush A.J., Kritchevsky S.B., Harris T., Stone K., et al. Magnesium intake from food and supplements is associated with bone mineral density in healthy older white subjects. J Am Geriatr Soc 2005, 53:1875-1880.
140. Barbagallo M., Dominguez L.J., Galioto A., Pineo A., Belvedere M. Oral magnesium supplementation improves vascular function in elderly diabetic patients. Magnes Res 2010, 23:131-137.
141. Shechter M., Bairey Merz C.N., Stuehlinger H.G., Slany J., Pachinger O., Rabinowitz B. Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease. Am J Cardiol 2003, 91:517-521.
142. Falco C.N., Grupi C., Sosa E., Scanavacca M., Hachul D., Lara S., et al. Successful improvement of frequency and symptoms of premature complexes after oral magnesium administration. Arq Bras Cardiol 2012, 98:480-487.
143. Bashir Y., Sneddon J.F., Staunton H.A., Haywood G.A., Simpson I.A., McKenna W.J., et al. Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1993, 72:1156-1162.
144. Kass L., Weekes J., Carpenter L. Effect of magnesium supplementation on blood pressure: a meta-analysis. Eur J Clin Nutr 2012, 66:411-418.
145. Mooren F.C., Kruger K., Volker K., Golf S.W., Wadepuhl M., Kraus A. Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects-a double-blind, placebo-controlled, randomized trial. Diabetes Obes Metab 2011, 13:281-284.
146. Guerrero-Romero F., Tamez-Perez H.E., Gonzalez-Gonzalez G., Salinas-Martinez A.M., Montes-Villarreal J., Trevino-Ortiz J.H., et al. Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab 2004, 30:253-258.
147. Aydin H., Deyneli O., Yavuz D., Gozu H., Mutlu N., Kaygusuz I., et al. Short-term oral magnesium supplementation suppresses bone turnover in postmenopausal osteoporotic women. Biol Trace Elem Res 2010, 133:136-143.
148. Galloe A.M., Rasmussen H.S., Jorgensen L.N., Aurup P., Balslov S., Cintin C., et al. Influence of oral magnesium supplementation on cardiac events among survivors of an acute myocardial infarction. BMJ 1993, 307:585-587.
149. Schurgers L.J., Cranenburg E.C., Vermeer C. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost 2008, 100:593-603.
150. Schurgers L.J., Uitto J., Reutelingsperger C.P. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. Trends Mol Med 2013, 19:217-226.
151. Gutierrez O.M. Increased serum phosphate and adverse clinical outcomes: unraveling mechanisms of disease. Curr Opin Nephrol Hypertens 2011, 20:224-228.
152. Linefsky J.P., O'Brien K.D., Katz R., De Boer I.H., Barasch E., Jenny N.S., et al. Association of serum phosphate levels with aortic valve sclerosis and annular calcification: the cardiovascular health study. J Am Coll Cardiol 2011, 58:291-297.
153. Adeney K.L., Siscovick D.S., Ix J.H., Seliger S.L., Shlipak M.G., Jenny N.S., et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009, 20:381-387.
154. Thompson G.R., Partridge J. Coronary calcification score: the coronary-risk impact factor. Lancet 2004, 363:557-559.
155. Detrano R., Guerci A.D., Carr J.J., Bild D.E., Burke G., Folsom A.R., et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008, 358:1336-1345.
156. Geleijnse J.M., Vermeer C., Grobbee D.E., Schurgers L.J., Knapen M.H., vanderMeer I.M., et al. Dietary intake of menaquinone is associated with areduced risk of coronary heart disease: the Rotterdam Study. J Nutr 2004, 134:3100-3105.
157. Gast G.C., de Roos N.M., Sluijs I., Bots M.L., Beulens J.W., Geleijnse J.M., et al. Ahigh menaquinone intake reduces the incidence of coronary heart disease. Nutr Metab Cardiovasc Dis 2009, 1:504-510.
158. Beulens J.W., Bots M.L., Atsma F., Bartelink M.L., Prokop M., Geleijnse J.M., et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis 2009, 203:489-493.
159. Lerner R.G., Aronow W.S., Sekhri A., Palaniswamy C., Ahn C., Singh T., et al. Warfarin use and the risk of valvular calcification. J Thromb Haemost 2009, 7:2023-2027.
160. Palaniswamy C., Sekhri A., Aronow W.S., Kalra A., Peterson S.J. Association of warfarin use with valvular and vascular calcification: a review. Clin Cardiol 2011, 34:74-81.
161. Dalmeijer G.W., van der Schouw Y.T., Magdeleyns E., Ahmed N., Vermeer C., Beulens J.W. The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein. Atherosclerosis 2012, 22:397-402.
162. Westenfeld R., Krueger T., Schlieper G., Cranenberg E.C., Magdeleyns E.J., Heidenreich S., et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: A randomized trial. Am J Kidney Dis 2012, 59:186-195.
163. Pilkey R.M., Morton A.R., Boffa M.B., Noordhof C., Day A.G., Su Y., et al. Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis 2007, 49:432-439.
164. Cranenburg E.C., Schurgers L.J., Uiterwijk H.H., Beulens J.W., Dalmeijer G.W., Westerhuis R., et al. Vitamin K intake and status are low in hemodialysis patients. Kidney Int 2012, 82:605-610.
165. Vermeer C. Vitamin K: the effect on health beyond coagulation-an overview [epub ahead of print]. Food Nutr Res, accessed May 24, 2013. http://dx.doi.org/10.3402/fnr.v56i0.5329.
166. Matias P.J., Ferreira C., Jorge C., Borges M., Aires I., Amaral T., et al. 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular riskmarkers in haemodialysis patients. Nephrol Dial Transplant 2009, 24:611-618.
167. Garcia-Canton C., Bosch E., Ramirez A., Gonzalez Y., Auyanet I., Guerra R., et al. Vascular calcification and 25-hydroxyvitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant 2011, 26:2250-2256.
168. Zagura M., Serg M., Kampus P., Zilmer M., Eha J., Unt E., et al. Aortic stiffness and vitamin D are independent markers of aortic calcification in patients with peripheral arterial disease and in healthy subjects. Eur J Vasc Endovasc Surg 2011, 42:689-695.
169. Lee S.Y., Kim H.Y., Gu S.W., Kim H.J., Yang D.H. 25-hydroxyvitamin D levels and vascular calcification in predialysis and dialysis patients with chronic kidney disease. Kidney Blood Press Res 2012, 35:349-354.
170. Naves-Diaz M., Cabezas-Rodriguez I., Barrio-Vazquez S., Fernandez E., Diaz-Lopez J.B., Cannata-Andia J.B. Low calcidiol levels and risk of progression of aortic calcification. Osteoporos Int 2012, 23:1177-1182.
171. Schmidt N., Brandsch C., Kuhne H., Thiele A., Hirche F., Stangl G.I. Vitamin D receptor deficiency and low vitamin D diet stimulate aortic calcification and osteogenic key factor expression in mice. PLoS One 2012, 7:e35316.
172. Zittermann A., Koerfer R. Protective and toxic effects of vitamin D on vascular calcification: clinical implications. Mol Aspects Med 2008, 29:423-432.
173. Vieth R. Vitamin D and cancer mini-symposium: the risk of additional vitamin D. Ann Epidemiol 2009, 19:441-445.
174. Sampathkumar K., Selvam M., Sooraj Y.S., Gowthaman S., Ajeshkumar R.N. Extended release nicotinic acid - a novel oral agent for phosphate control. Int Urol Nephrol 2006, 38:171-174.
175. Aramwit P., Srisawadwong R., Supasyndh O. Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients. J Nephrol 2012, 25:354-362.
176. Edalat-Nejad M., Zameni F., Talaiei A. The effect of niacin on serum phosphorus levels in dialysis patients. Indian J Nephrol 2012, 22:174-178.
177. Rennick A., Kalakeche R., Seel L., Shepler B. Nicotinic Acid and nicotinamide: a review of their use for hyperphosphatemia in dialysis patients. Pharmacotherapy 2013, 33:683-690.
178. Maccubbin D., Tipping D., Kuznetsova O., Hanlon W.A., Bostom A.G. Hypophosphatemic effect of niacin in patients without renal failure: A randomized trial. Clin J Am Soc Nephrol 2010, 5:582-589.
179. Hu S., Shearer G.C., Steffes M.W., Harris W.S., Bostom A.G. Once-daily extended-release niacin lowers serum phosphorus concentrations in patients with metabolic syndrome dyslipidemia. Am J Kidney Dis 2011, 57:181-182.
180. Bostom A.G., Maclean A.A., Maccubbin D., Tipping D., Giezek H., Hanlon W.A. Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes. J Clin Lipidol 2011, 5:281-287.
181. Kuboyama N., Watanabe Y., Yamaguchi M., Sato K., Suzuki T., Akiba T. Effects of niceritrol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant 1999, 14:610-614.
182. Wu K.I., Bacon R.A., Al-Mahrouq H.A., Kempson S.A. Nicotinamide as a rapid-acting inhibitor of renal brush-border phosphate transport. Am J Physiol 1988, 255:F15-F21.
183. Katai K., Tanaka H., Tatsumi S., Fukunaga Y., Genjida K., Morita K., et al. Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 1999, 14:1195-1201.
184. Eto N., Miyata Y., Ohno H., Yamashita T. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 2005, 20:1378-1384.
185. Kempson S.A. 5-Methylnicotinamide inhibits renal brush-border phosphate transport with no change in NAD. Am J Physiol 1986, 251:F520-F527.
186. Lavigne P.M., Karas R.H. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 2013, 61:440-446.
187. Voight B.F., Peloso G.M., Orho-Melander M., Frikke-Schmidt R., Barbalic M., Jensen M.K., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012, 380:572-580.
188. Briel M., Ferreira-Gonzalez I., You J.J., Karanicolas P.J., Aki E.A., Wu P., et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009, 338:b92.
189. Ganji S.H., Qin S., Zhang L., Kamanna V.S., Kashyap M.L. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009, 202:68-75.
190. Wu B.J., Chen K., Barter P.J., Rye K.A. Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. Circulation 2012, 125:150-158.
191. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013, 34:1279-1291.
192. Wierzbicki A.S. Dyslipidaemia: Failure to THRIVE: the end for niacin?. Nat Rev Cardiol 2013, 10:246-247.
193. Lavie C.J., DiNicolantonio J.J., Milani R.V., O'Keefe J.H. Niacin therapy lives for another day-maybe?. J Am Coll Cardiol 2013, 61:2197-2198.
194. Hattenhauer O., Traebert M., Murer H., Biber J. Regulation of small intestinal Na-P(i) type IIb cotransporter by dietary phosphate intake. Am J Physiol 1999, 277:G756-G762.
195. Capuano P., Radanovic T., Wagner C.A., Bacic D., Kato S., Uchiyama Y., et al. Intestinal and renal adaptation to a low-Pi diet of type II NaPi cotransporters in vitamin D receptor- and 1 alphaOHase-deficient mice. Am J Physiol Cell Physiol 2005, 288:C429-C434.
196. Giral H., Caldas Y., Sutherland E., Wilson P., Breusegem S., Barry N., et al. Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate. Am J Physiol Renal Physiol 2009, 297:F1466-F1475.